Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1 - PubMed (original) (raw)
doi: 10.1038/gt.2010.121. Epub 2010 Aug 26.
Affiliations
- PMID: 20739958
- DOI: 10.1038/gt.2010.121
Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1
B Huang et al. Gene Ther. 2011 Feb.
Abstract
Recent developments in the field of oncolytic or tumor-selective viruses have meant that the clinical applications of these agents are now being considered in more detail. Like most cancer therapies it is likely that they will be used primarily in combination with other therapeutics. Although several reports have shown that oncolytic viruses can synergize with chemotherapies within an infected cancer cell, it would be particularly important to determine whether factors released from infected cells could enhance the action of chemotherapies at a distance. Here, we demonstrate in vitro synergy between oncolytic vaccinia and taxanes. However, we also show, for the first time, that this synergy is at least partly due to the release of factors from the infected cells that are capable of sensitizing surrounding cells to chemotherapy. Several cellular factors were identified as being mediators of this bystander effect, including type I interferon released soon after infection and high-mobility group protein B1 (HMGB1) released after cell death. This represents the first description of these mechanisms for beneficial interactions between viral and traditional tumor therapies. These data may provide a direct basis for the design of clinical trials with agents currently in the clinic, as well as providing insight into the development of next generation viral vectors.
Similar articles
- Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D, Nawa A, Tanino T, Goshima F, Luo CH, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Tsurumi T, Nishiyama Y, Kikkawa F. Ishida D, et al. Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014. Epub 2009 Jul 14. Cancer Lett. 2010. PMID: 19604626 - A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S, Guo ZS, O'Malley ME, Yin X, Zeh HJ, Bartlett DL. Yang S, et al. Gene Ther. 2007 Apr;14(8):638-47. doi: 10.1038/sj.gt.3302914. Epub 2007 Feb 1. Gene Ther. 2007. PMID: 17268533 - Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S, Gao L, Yeagy B, Reid T. Kumar S, et al. Curr Opin Mol Ther. 2008 Aug;10(4):371-9. Curr Opin Mol Ther. 2008. PMID: 18683102 Review. - Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
Thorne SH, Contag CH. Thorne SH, et al. Gene Ther. 2008 May;15(10):753-8. doi: 10.1038/gt.2008.42. Epub 2008 Mar 20. Gene Ther. 2008. PMID: 18356814 Review.
Cited by
- Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy.
De S, Ehrlich M. De S, et al. Genes (Basel). 2024 Sep 11;15(9):1193. doi: 10.3390/genes15091193. Genes (Basel). 2024. PMID: 39336785 Free PMC article. Review. - Strategies for engineering oncolytic viruses to enhance cancer immunotherapy.
Yin ZS, Wang Z. Yin ZS, et al. Front Pharmacol. 2024 Sep 6;15:1450203. doi: 10.3389/fphar.2024.1450203. eCollection 2024. Front Pharmacol. 2024. PMID: 39309012 Free PMC article. Review. - Recent progress in combination therapy of oncolytic vaccinia virus.
Mirbahari SN, Da Silva M, Zúñiga AIM, Kooshki Zamani N, St-Laurent G, Totonchi M, Azad T. Mirbahari SN, et al. Front Immunol. 2024 Mar 13;15:1272351. doi: 10.3389/fimmu.2024.1272351. eCollection 2024. Front Immunol. 2024. PMID: 38558795 Free PMC article. Review. - Oncolytic vaccinia virus and cancer immunotherapy.
Xu L, Sun H, Lemoine NR, Xuan Y, Wang P. Xu L, et al. Front Immunol. 2024 Jan 12;14:1324744. doi: 10.3389/fimmu.2023.1324744. eCollection 2023. Front Immunol. 2024. PMID: 38283361 Free PMC article. Review. - Recent advances in oncolytic virus therapy for hepatocellular carcinoma.
Zhu L, Lei Y, Huang J, An Y, Ren Y, Chen L, Zhao H, Zheng C. Zhu L, et al. Front Oncol. 2023 Apr 26;13:1172292. doi: 10.3389/fonc.2023.1172292. eCollection 2023. Front Oncol. 2023. PMID: 37182136 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources